BDBM493066 2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-(4-(hydroxymethyl)phenyl)acetamide::US10981911, Example 7

SMILES OCc1ccc(NC(=O)Cc2nc3cnc4[nH]ccc4c3n2[C@H]2CC[C@H](CC#N)CC2)cc1

InChI Key InChIKey=SMDPPQPEXWEBHM-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 493066   

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.100nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 13.3nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent